Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Vaccine Information Center

COVID-19 Vaccines: AstraZeneca Resumes Trial; Pfizer, BioNTech Look to Expand Study

Diana Ernst, RPh

September 25, 2020

The Medicines Health Regulatory Authority confirmed that the AZD1222 trial could proceed after a UK committee concluded its investigations.

Infectious Diseases Information Center

Remdesivir Emergency Use Authorization Expanded to Include All Hospitalized COVID-19 Patients

Diana Ernst, RPh

September 4, 2020

Previously, the EUA limited use to patients with severe COVID-19 disease.

Influenza Information Center

ACIP: Influenza Vaccination Recommendations for 2020-2021

Diana Ernst, RPh

September 2, 2020

Influenza vaccination should occur by the end of October, if possible.

Infectious Diseases Information Center

Phase 3 Trial of COVID-19 Vaccine Candidate mRNA-1273 Begins

Diana Ernst, RPh

July 30, 2020

The trial, which is the first to be implemented under Operation Warp Speed, is expected to enroll around 30,000 adults and will be conducted at multiple clinical research sites across the US.

Infectious Diseases Information Center

FDA: Risk of Methanol Toxicity With Certain Hand Sanitizers

Diana Ernst, RPh

July 16, 2020

Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.

Vaccine Information Center

FDA Fast-Tracks Two mRNA-Based COVID-19 Vaccine Candidates

Diana Ernst, RPh

July 15, 2020

The FDA has granted Fast Track designation to 2 of Pfizer and BioNTech’s vaccine candidates against COVID-19.

Infectious Diseases Information Center

Study to Assess Antiviral Antibody Cocktail for COVID-19 Prevention Begins

Diana Ernst, RPh

July 9, 2020

A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

Neurology Information Center

Galcanezumab Linked to Improved Work Productivity in Patients With Migraine

Diana Ernst, RPh

June 22, 2020

Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.

Sleep Information Center

Dayvigo Now Available for Insomnia Treatment

Diana Ernst, RPh

June 16, 2020

Dayvigo (lemborexant; Eisai) is now available for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.

Infectious Diseases Information Center

Early Data Show Potential Benefit of Acalabrutinib in Severe COVID-19

Diana Ernst, RPh

June 10, 2020

Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.

Next post in Infectious Diseases Information Center